(Nasdaq: NTRB) Comes Out Firing On A Major Green Push Early Monday (Breaking News)

Nutriband Inc. (Nasdaq: NTRB) is pushing green hard early

Any content you receive is for information purposes only. Always conduct your own research. *Sponsored by Nutriband Inc. (Nasdaq: NTRB) Comes Out Firing On A Major Green Push Early Monday (Breaking News) *Get Our Updates Faster—Tap Here To Receive SMS Alerts* December 29th Greetings, Friend! Nutriband Inc. (Nasdaq: NTRB) is pushing green hard Monday AM. Could is it be because of strong breaking news? Check this out: Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5Mn USD to EarthVision Bio Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition The expected closing date for the transaction is Dec 31, 2025. ORLANDO, Fla., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5Mn USD to EarthVision Bio. Earthvision Bio has developed and are commercializing a new category of sustainable products created by Dr. Gordon Moore, the founder of Intel (NASDAQ: INTC), and Dr. Hans Franke, who was board chairman for Chevron Europe. The Company has developed a sustainable way to replace plastic, molded fiber, wood, and paper products with Earth-friendly alternatives. Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition. Nutriband Inc. will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fent-a-nyl which has the potential to be the world's first and only abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fent-a-nyl patches. AVERSA Fentanyl has the potential to reach annual US sales of $80Mn to $200Mn. Read the full article here. Don't forget. NTRB has a low float. With fewer than 5Mn shares in its float, volatility potential could be extremely heightened on a daily basis (and especially after strong news). Take a moment to review my initial (Nasdaq: NTRB) report below and consider this profile for your radar. ----- It's Monday AM and there's zero time to waste getting into today's Nasdaq profile.  First off, this is a low float idea just over 4Mn shares in its float. This means volatility potential could be significantly heightened. Furthermore, two months ago, this Nasdaq idea saw an analyst reiterate a major $15 target. From its closing valuation Friday, that target suggests a potential upside of 200+%. And just to fan the flames a bit more, this dynamo blazed a jaw-dropping $7.50+ surge in just two days back in January after one of my alerts. Now, that's not say the same thing will happen again, but it's more than enough reason as to why Nutriband Inc. (Nasdaq: NTRB) is climbing my watchlist this week. Another reason for NTRB rising my watchlist? Part of its due to its innovative approach to transdermal drug delivery and its potential to revolutionize patient care, particularly in the field of pain management and abuse prevention. The company's primary focus is on developing a portfolio of transdermal pharmaceutical products, with its flagship product being an abuse-deterrent fent-a-nyl patch incorporating their proprietary AVERSA™ technology. This technology is designed to prevent abuse, misuse, diversion, and accidental exposure of drugs with high abuse potential, addressing a critical issue in the o-pioid crisis. Furthermore, the company believes this technology has broad applicability to any therapeutic patch where deterring abuse and accidental misuse by children and pets are valuable attributes. AVERSA™ abuse deterrent transdermal technology incorporates aversive agents to prevent the Abuse, DiVERsion, MiSuse and Accidental exposure of drugs with abuse potential such as opioids Upon approval of AVERSA™ fent-a-nyl, the company expects that the FDA will consider requiring all fent-a-nyl patches be abuse deterrent as was required for all Oxy-con-tin generics Pipeline products include AVERSA™ buprenorphine and AVERSA™ meth-yl-phenidate According to Health Advances’ assessment and upon approval by the United States FDA, Aversa Fent-a-nyl will be priced competitively with generic fent-a-nyl patches and is expected to reach peak annual sales of $200Mn. If non-ADF transdermal fent-a-nyl products lose marketing approval, Aversa would have greater pricing flexibility and could generate >$800Mn in revenue. Aversa Pipeline Learn More About The Company Here: NTRB Presentation. NTRB Website. Nutriband's potential for growth and market impact is supported by several key potential catalysts: #1. A Low Float Scenario: With roughly 4.12Mn shares in its float, volatility potential could become heightened at the drop of a hat. #2. A $15 Analyst Target: Back in October, an analyst at Noble Capital Markets reiterated his $15 target for NTRB. From Friday's closing valuation, this target projects NTRB to have a 200+% potential upside. #3. Nutriband Inc. Signs LOI with Qvanta Group to Explore Quantum-AI Collaboration for Abuse-Deterrent Innovation Nutriband jointly explores secure AI analytics, data integrity, and quantum-ready modeling to advance abuse-deterrent technologies. The non-binding LOI aligns with federal priorities on fent-a-nyl, AI, and quantum computing. Qvanta brings quantum-AI cy-ber-security and high-performance infrastructure to potentially bolster Nutriband’s research and product development. #4. Nutriband Announces Positive FDA Dialogue Advancing AVERSA Fent-a-nyl Patch. Nutriband reported a productive FDA meeting on AVERSA™ Fent-a-nyl, outlining insights for CMC, IND to NDA 505(b)(2) pathway, and manufacturing validation. The FDA endorsed a 505(b)(2) approach, suggested reference standards, and advised on batch plans, stability testing, and product specifications. The agency also reviewed in vitro manipulation studies to gauge abuse-deterrence and offered ongoing support for addressing fent-a-nyl exposure risks. Nutriband will incorporate feedback and advance toward an IND for a Human Abuse Potential study, aiming to become a first-approved abuse-deterrent fent-a-nyl patch worldwide. #5. Nutriband Advances Branding Partnership For Global AVERSA Fent-a-nyl Patch Commercial Launch. Nutriband Inc., through its 4P Therapeutics subsidiary, has partnered with Brand Institute, the global leader in pharmaceutical brand identity development, to create the worldwide commercial brand name for its abuse-deterrent fent-a-nyl transdermal system, AVERSA™.  This collaboration marks a vital step toward commercialization of the world’s first abuse-deterrent opioid patch. With Brand Institute’s unmatched expertise and Drug Safety Institute’s regulatory support, Nutriband strengthens its path to market while ensuring safe, distinctive, and compliant branding for its innovative opioid abuse prevention technology. ----- Coverage is officially kicked-off again on Nutriband Inc. (Nasdaq: NTRB). When updates are available, we'll get them out quickly. Talk soon. All the best, Dane James Editor Market Pulse Today (Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.) *MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, MPT is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile MPT brings to your attention. Any emojis used do not have a specific defined meaning, and may be used inconsistently. We do not provide personalized in-vest-ment advice, are not in-vest-ment advisors, and any profiles we mention are not suitable for all in-vest-ors. Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired for a period beginning on 10/28/2025 and ending on 12/29/2025 to publicly disseminate information about (NTRB:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid nine thousand USD ("Funds"). To date, including under the previously described agreement, Thousand Sun Media LLC has been paid forty four thousand USD ("Funds"). These Funds were part of the funds that TD Media LLC received from Nutriband Inc., the issuer of (NTRB:US). Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (NTRB:US). Please see important disclosure information here: https://marketpulsetoday.com/disclosure/ntrb-luecl/#details

Market Pulse Today | 1314 E LAS OLAS BLVD UNIT #2170 | FORT LAUDERDALE, FL 33301 US Unsubscribe | Update Profile | Our Privacy Policy | Constant Contact Data Notice